Xtandi is often compared to other androgen receptor inhibitors such as apalutamide and darolutamide. While all these drugs are effective in treating mCRPC and nmCRPC, they may differ in their side effect profiles and specific indications. For instance, apalutamide is specifically approved for nmCRPC, while darolutamide is known for having fewer drug-drug interactions.
